Technical Analysis for OLMA - Olema Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Resistance | Bearish | 3.15% | |
| Fell Below 20 DMA | Bearish | 3.15% | |
| 180 Bearish Setup | Bearish Swing Setup | 3.15% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 3.15% | |
| New Uptrend | Bullish | 3.15% | |
| Multiple of Ten Bearish | Other | 3.15% | |
| Gapped Up | Strength | 3.15% | |
| Upper Bollinger Band Touch | Strength | 3.15% | |
| Oversold Stochastic | Weakness | 3.15% | |
| Crossed Above 20 DMA | Bullish | -0.10% |
| Alert | Time |
|---|---|
| Up 2% | 6 minutes ago |
| Down 1% | 24 minutes ago |
| Up 1% | 36 minutes ago |
| 60 Minute Opening Range Breakdown | about 23 hours ago |
| Down 3% | about 23 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/20/2024
Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is an orally available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer. Olema is headquartered in San Francisco.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Breast Cancer Treatment Of Breast Cancer Epidermal Growth Factor Receptor Hormones Targeted Therapy Her2 Her2/Neu Estrogen Antiestrogens Estrogen Receptor Selective Estrogen Receptor Degraders Fulvestrant
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Breast Cancer Treatment Of Breast Cancer Epidermal Growth Factor Receptor Hormones Targeted Therapy Her2 Her2/Neu Estrogen Antiestrogens Estrogen Receptor Selective Estrogen Receptor Degraders Fulvestrant
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 17.7911 |
| 52 Week Low | 5.05 |
| Average Volume | 880,120 |
| 200-Day Moving Average | 12.23 |
| 50-Day Moving Average | 10.97 |
| 20-Day Moving Average | 10.12 |
| 10-Day Moving Average | 10.21 |
| Average True Range | 0.84 |
| RSI (14) | 44.13 |
| ADX | 27.02 |
| +DI | 21.07 |
| -DI | 19.78 |
| Chandelier Exit (Long, 3 ATRs) | 8.87 |
| Chandelier Exit (Short, 3 ATRs) | 11.69 |
| Upper Bollinger Bands | 11.09 |
| Lower Bollinger Band | 9.16 |
| Percent B (%b) | 0.36 |
| BandWidth | 19.07 |
| MACD Line | -0.31 |
| MACD Signal Line | -0.31 |
| MACD Histogram | -0.0027 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 12.24 | ||||
| Resistance 3 (R3) | 12.42 | 11.81 | 11.84 | ||
| Resistance 2 (R2) | 11.81 | 11.20 | 11.72 | 11.70 | |
| Resistance 1 (R1) | 10.83 | 10.83 | 10.53 | 10.65 | 11.57 |
| Pivot Point | 10.22 | 10.22 | 10.07 | 10.13 | 10.22 |
| Support 1 (S1) | 9.24 | 9.61 | 8.94 | 9.06 | 8.13 |
| Support 2 (S2) | 8.63 | 9.24 | 8.54 | 8.00 | |
| Support 3 (S3) | 7.65 | 8.63 | 7.86 | ||
| Support 4 (S4) | 7.47 |
